

Contents

| | |
|------------------------------------|-------------|
| <i>Contributor contact details</i> | <i>xvii</i> |
|------------------------------------|-------------|

| | |
|----------------|--------------|
| <i>Preface</i> | <i>xxiii</i> |
|----------------|--------------|

Part Sources, properties, modification and processing of natural-based polymers

| | |
|--------------------------------------------------------------------------|---|
| Polysaccharides as carriers of bioactive agents for medical applications | 3 |
|--------------------------------------------------------------------------|---|

R. PAWAR, W. JADHAV, S. BHUSARE and R. BORADE, Dnyanopasak College, India, S. FARBER, D. ITZKOWITZ and A. DOMB, The Hebrew University, Jerusalem, Israel

| | | |
|------|--------------------------------------------------|----|
| | Introduction | 3 |
| 1.2 | Starch | 6 |
| 1.3 | Cellulose | |
| 1.4 | Heparinoid (sulfated polysaccharides) | 8 |
| 1.5 | Dextran | 10 |
| 1.6 | Pectin | 12 |
| 1.7 | Arabinogalactan | 13 |
| 1.8 | Drug conjugated polysaccharides | 15 |
| 1.9 | Polysaccharide dextrans | 19 |
| 1.10 | Mannan | 22 |
| 1.11 | Pullulan | 23 |
| 1.12 | Polysaccharide macromolecule–protein conjugates | 24 |
| 1.13 | Cationic polysaccharides for gene delivery | 25 |
| 1.14 | Diethylaminoethyl-dextran | 26 |
| 1.15 | Polysaccharide–oligoamine based conjugates | 27 |
| 1.16 | Chitosan | 27 |
| 1.17 | Applications of polysaccharides as drug carriers | 31 |
| 1.18 | Applications of dextran conjugates | 33 |
| 1.19 | Site-specific drug delivery | 38 |

| | | |
|------|----------------------------------------------------------------------------------------------------------------------------------|-----|
| 1.20 | Pectin drug site-specific delivery | 38 |
| 1.21 | Liposomal drug delivery | 40 |
| 1.22 | References | 45 |
| 2 | Purification of naturally occurring biomaterials | 54 |
| | M. N. GUPTA, Indian Institute of Technology Delhi, India | |
| 2.1 | Introduction | 54 |
| 2.2 | Classes of naturally occurring biomaterials | 55 |
| 2.3 | Downstream processing of small molecular weight natural products | 57 |
| 2.4 | Purification strategies for proteins | 60 |
| 2.5 | Purification of lipids | 67 |
| 2.6 | Purification of polysaccharides | 71 |
| 2.7 | Purification of nucleic acids | 72 |
| 2.8 | Purification of complex biomaterials | 75 |
| 2.9 | Future trends | 76 |
| 2.10 | Acknowledgement | 77 |
| 2.11 | Sources of further information | 77 |
| 2.12 | References | 78 |
| 3 | Processing of starch-based blends for biomedical applications | 85 |
| | R. A. SOUSA, V. M. CORRELO, S. CHUNG, N. M. NEVES, J. F. MANO and R. L. REIS, 3B's Research Group, University of Minho, Portugal | |
| 3.1 | Introduction | 85 |
| 3.2 | Starch | 85 |
| 3.3 | Starch-based blends | 88 |
| 3.4 | Conclusions | 98 |
| 3.5 | References | 99 |
| 4 | Controlling the degradation of natural polymers for biomedical applications | |
| | H. S. AZEVEDO, T. C. SANTOS and R. L. REIS, 3B's Research Group, University of Minho, Portugal | |
| 4.1 | Introduction | 106 |
| 4.2 | The importance of biodegradability of natural polymers in biomedical applications | 106 |
| 4.3 | Degradation mechanisms of natural polymers and metabolic pathways for their disposal in the body | |
| 4.4 | Assessing the <i>in vitro</i> and <i>in vivo</i> biodegradability of natural polymers | 111 |
| 4.5 | Controlling the degradation rate of natural polymers | 120 |

| | | |
|-----|--------------------|-----|
| 4.6 | Concluding remarks | 124 |
| 4.7 | Acknowledgements | 125 |
| 4.8 | References | 125 |

| | | |
|------|-------------------------------------------------------------------------|-----|
| 5 | Smart systems based on polysaccharides | |
| | M. N. GUPTA and S. RAGHAVA, Indian Institute of Technology Delhi, India | |
| 5.1 | What are smart materials? | 129 |
| 5.2 | Chitin and chitosan | 131 |
| 5.3 | Alginates | 136 |
| 5.4 | Carrageenans | 140 |
| 5.5 | Other miscellaneous smart polysaccharides and their applications | 145 |
| 5.6 | Polysaccharide-based composite materials | 146 |
| 5.7 | Future trends | 149 |
| 5.8 | Acknowledgement | 152 |
| 5.9 | Sources of further information | 152 |
| 5.10 | References | 154 |

Part II Surface modification and biomimetic coatings

| | | |
|-----|-----------------------------------------------------------------------------------------------------|-----|
| 6 | Surface modification for natural-based biomedical polymers | 165 |
| | I. PASHKULEVA, P. M. LÓPEZ-PÉREZ and R. L. REIS, 3B's Research Group, University of Minho, Portugal | |
| 6.1 | Introduction | 165 |
| 6.2 | Some terms and classifications | 165 |
| 6.3 | Wet chemistry in surface modification | 167 |
| 6.4 | Physical methods for surface alterations | 171 |
| 6.5 | Grafting | 177 |
| 6.6 | Bio-approaches: Mimicking the cell-cell interactions | 179 |
| 6.7 | Future trends | 186 |
| 6.8 | Acknowledgements | 186 |
| 6.9 | References | 186 |

| | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 7 | New biomineralization strategies for the use of natural-based polymeric materials in bone-tissue engineering | |
| | I. B. LEONOR, S. GOMES, P. C. BESSA, J. F. MANO, R. L. REIS, 3B's Research Group, University of Minho, Portugal and M. Casal, CBMA – Molecular and Environmental Biology Center, University of Minho, Portugal | |
| 7. | Introduction | 193 |

Contents

| | | |
|-----|-------------------------------------------------------------|-----|
| 7.2 | The structure, development and mineralization of bone | 194 |
| 7.3 | Bone morphogenetic proteins in tissue engineering | 201 |
| 7.4 | Bio-inspired calcium-phosphate mineralization from solution | 206 |
| 7.5 | General remarks and future trends | 216 |
| 7.6 | Acknowledgments | 217 |
| 7.7 | References | 217 |

8 Natural-based multilayer films for biomedical applications

C. PICART, Université Montpellier, France

| | | |
|-----|------------------------------------------------------------------------------|-----|
| 8.1 | Introduction | 231 |
| 8.2 | Physico-chemical properties | 234 |
| 8.3 | Different types of natural-based multilayer films for different applications | 240 |
| 8.4 | Bioactivity, cell adhesion, and biodegradability properties | 244 |
| 8.5 | Modulation of film mechanical properties | 248 |
| 8.6 | Future trends | 250 |
| 8.7 | Sources of further information and advice | 251 |
| 8.8 | References | 252 |

9 Peptide modification of polysaccharide scaffolds for targeted cell signaling

S. LÉVESQUE, R. WYLIE, Y. AIZAWA and M. SHOICHET, University of Toronto, Canada

| | | |
|-----|--------------------------------------------------------|-----|
| 9.1 | Introduction | 260 |
| 9.2 | Polysaccharide scaffolds in tissue engineering | 265 |
| 9.3 | Peptide immobilization | 267 |
| 9.4 | Measurement | 272 |
| 9.5 | Challenges associated with peptide immobilization | 274 |
| 9.6 | Tissue engineering approaches targeting cell signaling | 275 |
| 9.7 | References | 277 |

Part III Biodegradable scaffolds for tissue regeneration

10 Scaffolds based on hyaluronan derivatives in biomedical applications

E. TOGNANA, Fidia Advanced Biopolymers s.r.l., Italy

| | | |
|------|--------------------------------------------------------|-----|
| 10.1 | Introduction | 291 |
| 10.2 | Hyaluronan | 291 |
| 10.3 | Hyaluronan-based scaffolds for biomedical applications | 293 |
| 10.4 | Clinical applications | 298 |

| | | |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 10.5 | Future trends | 308 |
| 10.6 | Sources of further information and advice | 309 |
| 10.7 | References | 310 |
| | Electrospun elastin and collagen nanofibers and their application as biomaterials | 315 |
| | R. SALLACH and E. CHAIKOF, Emory University/Georgia Institute of Technology, USA | |
| 11.1 | Introduction | 315 |
| 11.2 | Electrospinning as a biomedical fabrication technology | 316 |
| 11.3 | Generation of nanofibers with controlled structures and morphology | |
| 1.4 | Generation of collagen and elastin small-diameter fibers and fiber networks | 318 |
| 11.5 | Biological role of elastin | 321 |
| 11.6 | Generation of crosslinked fibers and fiber networks | 328 |
| 11.7 | Multicomponent electrospun assemblies | 329 |
| 11.8 | Future trends | 331 |
| 11.9 | References | 332 |
| 12 | Starch-polycaprolactone based scaffolds in bone and cartilage tissue engineering approaches | |
| | M. E. GOMES, J. T. OLIVEIRA, M. T. RODRIGUES, M. I. SANTOS, K. TUZLAKOGLU, C. A. VIEGAS, I. R. DIAS and R. L. REIS, 3B's Research Group, University of Minho, Portugal | |
| 12.1 | Introduction | 337 |
| 12.2 | Starch+ ϵ -polycaprolactone (SPCL) fiber meshes | 338 |
| 12.3 | SPCL-based scaffold architecture, stem cell proliferation and differentiation | 339 |
| 12.4 | <i>In vivo</i> functionality of SPCL fiber-mesh scaffolds | 341 |
| 12.5 | Cartilage tissue engineering using SPCL fiber-mesh scaffolds | 342 |
| 12.6 | Advanced approaches using SPCL scaffolds for bone tissue engineering aiming at improved vascularization | 346 |
| 12.7 | Conclusions | 350 |
| 12.8 | Acknowledgments | 351 |
| 12.9 | References | 351 |
| 13 | Chitosan-based scaffolds in orthopedic applications | |
| | K. TUZLAKOGLU and R. L. REIS, 3B's Research Group, University of Minho, Portugal | |
| 13. | Introduction: Chemical and physical structure of chitosan and its derivatives | |

| | | |
|-------|-----------------------------------------------------------------------------------------------------------|-----|
| | Production methods for scaffolds based on chitosan and its composites or blends | 358 |
| 13.3 | Orthopedic applications | 365 |
| 13.4 | Conclusions and future trends | 369 |
| 13.5 | Acknowledgements | 369 |
| 13.6 | References | 369 |
| 14 | Elastin-like systems for tissue engineering | 374 |
| | J. RODRIGUEZ-CABELLO, A. RIBEIRO, J. REGUERA, A. GIROTTI and A. TESTERA, Universidad de Valladolid, Spain | |
| 14.1 | Introduction | 374 |
| 14.2 | Genetic engineering of protein-based polymers | 375 |
| 14.3 | Genetic strategies for synthesis of protein-based polymers | 376 |
| | State-of-the-art in genetically-engineered protein-based polymers (GEBPs) | 377 |
| 14.5 | Elastin-like polymers | 377 |
| 14.6 | Self-assembly behaviour of peptides and proteins | 379 |
| 14.7 | Self-assembly of elastin-like polymers (ELPs) | 379 |
| 14.8 | Biocompatibility of ELPs | 381 |
| 14.9 | Biomedical applications | 382 |
| 14.10 | ELPs for drug delivery | 382 |
| 14.11 | Tissue engineering | 383 |
| 14.12 | Self-assembling properties of ELPs for tissue engineering | 388 |
| 14.13 | Processability of ELPs for tissue engineering | 388 |
| 14.14 | Future trends | 389 |
| 14.15 | References | 391 |
| 15 | Collagen-based scaffolds for tissue engineering | 396 |
| | G. CHEN, N. KAWAZOE and T. TATEISHI, National Institute for Materials Science, Japan | |
| 15.1 | Introduction | 396 |
| 15.2 | Structure and properties of collagen | 396 |
| 15.3 | Collagen sponge | 397 |
| 15.4 | Collagen gel | 400 |
| 15.5 | Collagen–glycosaminoglycan (GAG) scaffolds | 402 |
| 15.6 | Acellularized scaffolds | 404 |
| 15.7 | Hybrid scaffolds | 405 |
| 15.8 | Future trends | 409 |
| 15.9 | References | 409 |

| | | |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 16 | Polyhydroxyalkanoate and its potential for biomedical applications | |
| | P. FURRER and M. ZINN, Swiss Federal Laboratories for Materials Testing and Research (Empa), Switzerland, and S. PANKE, Swiss Federal Institute of Technology (ETH), Switzerland | |
| 16.1 | Introduction | 416 |
| 16.2 | Biosynthesis | 417 |
| 16.3 | Chemical digestion of non-PHA biomass | 425 |
| 16.4 | Purification of PHA | 431 |
| 16.5 | Potential applications of PHA in medicine and pharmacy | 434 |
| 16.6 | Conclusions and future trends | 437 |
| 16.7 | References | 437 |
| 17 | Electrospinning of natural proteins for tissue engineering scaffolding | |
| | P. I. LELKES, M. LI, A. PERETS, L. LIN, J. HAN and D. WOERDEMAN, Drexel University, USA | |
| 17.1 | Introduction | 446 |
| 17.2 | The electrospinning process | 448 |
| 17.3 | Electrospinning natural animal polymers | 455 |
| 17.4 | Electrospinning blends of synthetic and natural polymers | 460 |
| 17.5 | Electrospinning novel natural 'green' plant polymers for tissue engineering | |
| 17.6 | Cellular responses to electrospun scaffolds: Does fiber diameter matter? | 474 |
| 17.7 | Conclusions and future trends | 474 |
| 17.8 | Sources of further information and advice | 475 |
| 17.9 | References | 476 |

Part IV Naturally-derived hydrogels: Fundamentals, challenges and applications in tissue engineering and regenerative medicine

| | | |
|------|-------------------------------------------------------------------------------------------------------------------|--|
| 18 | Hydrogels from polysaccharide-based materials: Fundamentals and applications in regenerative medicine | |
| | J. T. OLIVEIRA and R. L. REIS, 3B's Research Group, University of Minho, Portugal | |
| 18.1 | Introduction: Definitions and properties of hydrogels | |
| 18.2 | Applications of hydrogels produced from different polysaccharides in tissue engineering and regenerative medicine | |

| | | |
|-------|-----------------------------------------------------------------------------------------------------|-----|
| 18.3 | Agarose | 488 |
| 18.4 | Alginate | 489 |
| 18.5 | Carrageenan | 491 |
| 18.6 | Cellulose | 492 |
| 18.7 | Chitin/chitosan | 493 |
| 18.8 | Chondroitin sulfate | 495 |
| 18.9 | Dextran | 496 |
| 18.10 | Gellan | 497 |
| 18.11 | Hyaluronic acid | 498 |
| 18.12 | Starch | 500 |
| 18.13 | Xanthan | 501 |
| 18.14 | Conclusion | 502 |
| 18.15 | References | 503 |
| 19 | Alginate hydrogels as matrices for tissue engineering | |
| | H. PARK and K.-Y. LEE, Hanyang University, South Korea | |
| 19.1 | Introduction | 515 |
| 19.2 | Properties of alginate | 516 |
| 19.3 | Methods of gelling | 520 |
| 19.4 | Applications of alginate hydrogels in tissue engineering | 523 |
| 19.5 | Summary and future trends | 528 |
| 19.6 | References | 528 |
| 20 | Fibrin matrices in tissue engineering | |
| | B. TAWIL, H. DUONG and B. WU, University of California Los Angeles, USA | |
| 20.1 | Introduction | 533 |
| 20.2 | Fibrin formation | 534 |
| 20.3 | Fibrin use in surgery | 535 |
| 20.4 | Fibrin matrices to deliver bioactive molecules | 535 |
| 20.5 | Fibrin – cell constructs | 536 |
| 20.6 | Mechanical characteristics of fibrin scaffold | 540 |
| 20.7 | Future trends | 541 |
| 20.8 | Conclusions | 542 |
| 20.9 | References | 543 |
| 2 | Natural-based polymers for encapsulation of living cells: Fundamentals, applications and challenges | |
| | P. DE Vos, University Hospital of Groningen, The Netherlands | |
| 2.1 | Introduction | 549 |

| | | |
|------|--------------------------------------------------------------------|-----|
| 21.2 | Approaches of encapsulation: Materials and biocompatibility issues | 550 |
| 21.3 | Physico-chemistry of microcapsules and biocompatibility | 556 |
| 21.4 | Immunological considerations | 559 |
| 21.5 | Conclusions and future trends | 561 |
| 21.6 | Sources of further information and advice | 563 |
| 21.7 | References | 564 |

| | | |
|----|-----------------------------------------------|-----|
| 22 | Hydrogels for spinal cord injury regeneration | 570 |
|----|-----------------------------------------------|-----|

A. J. SALGADO and N. SOUSA, Life and Health Sciences Research Institute (ICVS), University of Minho, Portugal, and N. A. SILVA, N. M. NEVES and R. L. REIS, 3B's Research Group, University of Minho, Portugal

| | | |
|------|-----------------------------------------------------|-----|
| 22.1 | Introduction | 570 |
| 22.2 | Brief insights on central nervous system biology | 571 |
| 22.3 | Current approaches for SCI repair | 576 |
| 22.4 | Hydrogel-based systems in SCI regenerative medicine | 578 |
| 22.5 | Conclusions and future trends | 587 |
| 22.6 | Acknowledgements | 588 |
| 22.7 | References | 588 |

Part V Systems for the sustained release of molecules

| | | |
|----|----------------------------------------|--|
| 23 | Particles for controlled drug delivery | |
|----|----------------------------------------|--|

E. T. BARAN and R. L. REIS, 3B's Research Group, University of Minho, Portugal

| | | |
|------|----------------------------------------------------------------------|-----|
| 23.1 | Introduction | 597 |
| 23.2 | Novel particle processing methods | 597 |
| 23.3 | Hiding particles: The stealth principle | 602 |
| 23.4 | Finding the target | 604 |
| 23.5 | Delivery of bioactive agents at the target site and novel deliveries | 608 |
| 23.6 | Viral delivery systems | 611 |
| 23.7 | Conclusions | 612 |
| 23.8 | Acknowledgements | 613 |
| 23.9 | References | 613 |

| | | |
|----|---------------------------------------------------|--|
| 24 | Thiolated chitosans in non-invasive drug delivery | |
|----|---------------------------------------------------|--|

A. BERNKOP-SCHNÜRCH, Leopold-Franzens University, Austria

| | | |
|------|---------------------|-----|
| 24.1 | Introduction | 624 |
| 24.2 | Thiolated chitosans | 625 |

| | | |
|----------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 24.3 | Properties of thiolated chitosans | 625 |
| 24.4 | Drug delivery systems | 633 |
| 24.5 | <i>In vivo</i> performance | 634 |
| 24.6 | Conclusion | 638 |
| 24.7 | References | 639 |
| 25 | Chitosan–polysaccharide blended nanoparticles for controlled drug delivery | 644 |
| | J. M. ALONSO and F. M. GOYCOOLEA, Universidad de Santiago de Compostela, Spain, and I. HIGUERA-CIAPARA, Centro de Investigación en Alimentación y Desarrollo, Mexico | |
| 25.1 | Introduction | 644 |
| 25.2 | Polysaccharides in nanoparticle formation | 645 |
| 25.3 | Nanoparticles constituted by chitosan | 651 |
| 25.4 | Drug delivery properties and biopharmaceutical applications | 654 |
| 25.5 | Hybrid nanoparticles consisting of chitosan and other polysaccharides | 656 |
| 25.6 | Future trends | 668 |
| 25.7 | Sources of further information and advice | 668 |
| 25.8 | Acknowledgements | 671 |
| 25.9 | References | 671 |
| Part VI Biocompatibility of natural-based polymers | | |
| 26 | <i>In vivo</i> tissue responses to natural-origin biomaterials | |
| | T. C. SANTOS, A. P. MARQUES and R. L. REIS, 3B's Research Group, University of Minho, Portugal | |
| 26.1 | Introduction | 683 |
| 26.2 | Inflammation and foreign-body reactions to biomaterials | 684 |
| 26.3 | Role of host tissues in biomaterials implantation | 686 |
| 26.4 | Assessing the <i>in vivo</i> tissue responses to natural-origin biomaterials | 690 |
| 26.5 | Controlling the <i>in vivo</i> tissue reactions to natural-origin biomaterials | 693 |
| 26.6 | Final remarks | 695 |
| 26.7 | Acknowledgements | 695 |
| 26.8 | References | 695 |
| 27 | Immunological issues in tissue engineering | |
| | N. ROTTER, Ulm University, Germany | |
| 27 | Introduction | 699 |

| | | |
|-------|------------------------------------------------------------------------------------------------|-----|
| 27.2 | Immune reactions to biomaterials | 699 |
| 27.3 | Host reactions related to the implant site | 701 |
| 27.4 | Immune reactions to different types of cells | 701 |
| 27.5 | Immune reactions to <i>in vitro</i> engineered tissues | 704 |
| 27.6 | Immune protection of engineered constructs | 705 |
| 27.7 | Strategies directed towards reactions to biomaterials | 706 |
| 27.8 | Strategies directed towards reactions to implanted cells | 707 |
| 27.9 | Future trends | 709 |
| 27.10 | References | 710 |
| 28 | Biocompatibility of hyaluronic acid: From cell recognition to therapeutic applications | 716 |
| | K. GHOSH, Children's Hospital and Harvard Medical School, USA | |
| 28.1 | Introduction | 716 |
| 28.2 | Native hyaluronan | 717 |
| 28.3 | Therapeutic implications of native hyaluronan | 721 |
| 28.4 | Engineered hyaluronan | 722 |
| 28.5 | Implications for regenerative medicine | 727 |
| 28.6 | Conclusion | 728 |
| 28.7 | Future trends | 728 |
| 28.8 | References | 728 |
| 29 | Biocompatibility of starch-based polymers | 738 |
| | A. P. MARQUES, R. P. PIRACO and R. L. REIS, 3B's Research Group, University of Minho, Portugal | |
| 29.1 | Introduction | 738 |
| 29.2 | Starch-based polymers in the biomedical field | 740 |
| 29.3 | Cytocompatibility of starch-based polymers | 745 |
| 29.4 | Immunocompatibility of starch-based polymers | 748 |
| 29.5 | Conclusions | 752 |
| 29.6 | Acknowledgements | 753 |
| 29.7 | References | 753 |
| 30 | Vascularization strategies in tissue engineering | 761 |
| | M. I. SANTOS, and R. L. REIS, 3B's Research Group, University of Minho, Portugal | |
| 30.1 | Introduction | 761 |
| 30.2 | Biology of vascular networks – angiogenesis versus vasculogenesis | 761 |
| 30.3 | Vascularization: The hurdle of tissue engineering | 762 |
| 30.4 | Neovascularization of engineered bone | 763 |

xvi Contents

| | | |
|------|------------------------------------------------------------------------------|-----|
| | Strategies to enhance vascularization in engineered grafts | 765 |
| | <i>In vivo</i> models to evaluate angiogenesis in tissue engineered products | 774 |
| 30.7 | Future prospects | 776 |
| 30.8 | Sources of further information and advice | 776 |
| 30.9 | References | 776 |
| | <i>Index</i> | 781 |